California Cancer Reporting System Standards Volume I: Abstracting and Coding Procedures
Please refer to the reportability guide below for information on specific histologies and sites for tumors that are reportable or not reportable to the CCR.
California Cancer Registry Reportability Guide |
||||||
REPORTABLE TERMS |
||||||
Ambiguous Terminology Considered as Diagnostic of Cancer Exception: If the cytology is reported as “suspicious” and neither a positive biopsy nor a physician’s clinical impression supports the cytology findings, do not consider as diagnosis of cancer. |
|
|||||
The reportable terms noted above are used ONLY for reportability. These are not to be used for determining tumor extension/involvement or for determining histological classification. There are separate lists for those. |
||||||
SITE SPECIFIC REPORTABILITY GUIDE |
||||||
Site |
Histology |
Reference |
Reportable/Non-reportable Criteria |
|||
SKIN |
||||||
C44.0-C44.9 |
8000-8110 |
Volume One: Skin Reportability |
Has always been non-reportable |
|||
|
||||||
EXCEPTIONS: Reportable skin cancers include:
|
||||||
CERVIX |
||||||
C53.0-C53.9 |
Any morphology with behavior 2 |
Volume One: Definition of Cancer |
Reportable = Before 1996 |
|||
|
||||||
BENIGN BRAIN (NOTE: Benign Schwannoma section below) |
||||||
C70.0-70.9 C71.0-71.9 C72.0-C72.9 C75.1-C75.3 |
Behavior = 0 or 1 |
Volume One: Benign/Borderline Brain and CNS Tumors |
Reportable = 2001+ |
|||
Hemangioma, NOS and cavernous hemangiomas (9120/0 or 9121/0) |
SEER Program Manual SEER INQ #20130001 |
Reportable = 2001+ |
||||
Standard Setter Differences:
|
||||||
BENIGN SCHWANNOMAS |
||||||
C72.2-72.5 |
9560 Behavior=0 |
SEER and CDC |
Reportable = 2004+ (only report site codes C72.2-72.5) |
|||
C72.0 |
9560 Behavior=0 |
SEER SINQ #20130023 |
Reportable = 2011+ (expanded to include site code C72.0) |
|||
Per SEER instruction, we are to report benign schwannomas (9560/0) of the spinal cord (C72.0) and of the cranial nerves (C72.2 - C72.5); therefore, these are both reportable to the CCR. Benign schwannomas occurring anywhere else such as the peripheral nerves or spinal nerves are not reportable to the CCR. |
||||||
BORDERLINE OVARIAN |
||||||
C56.9 |
8442/1 8451/1 8462/1 8472/1 8473/1 |
Volume One: Borderline Ovarian Tumors |
Non-reportable = 2016+ Reportable = behavior /3 pre-2001 or behavior /1 for 2001-2015 |
|||
INTRAEPITHELIAL NEOPLASIA NOTE: (8077/2 and 8148/2) must be stated exactly as stated here. Grade III must be included in the diagnosis in order for these to be reportable. No variation in terms allowed. |
||||||
AIN III (anal intraepithelial neoplasia, Grade III or 3) |
||||||
C21.0 C21.1 |
8077/2, Grade III |
Volume One: In Situ Coding DSQC Memo #2001-03 DSQC Memo #2002-01 PAQC Memo #2012-03 |
Reportable = 2001+ |
|||
DIN III (ductal intraepithelial neoplasia, Grade III or 3) |
||||||
C50. |
8500/2, Grade III |
Volume One: In Situ Coding Coding DSQC Memo #2002-01 |
Reportable = 2001+ |
|||
LIN III (laryngeal intraepithelial neoplasia, Grade III or 3) |
||||||
C32. |
8077/2, Grade III |
Volume One: In Situ Coding DSQC Memo #2002-01 |
Reportable = 2001+ |
|||
LN III (breast lobular neoplasia, Grade III or 3) LIN III (breast lobular intraepithelial neoplasia, Grade III or 3) |
||||||
C50. |
8500/2, Grade III |
Volume One: In Situ Coding SEER Program Manual |
Reportable = 2016+ |
|||
PanIN-III (pancreatic intraepithelial neoplasia, Grade III or 3) |
||||||
C25. |
8500/2, Grade III |
Volume One: In Situ Coding |
Reportable = 2004+ |
|||
PeIN III (penile intraepithelial neoplasia, Grade III or 3) |
||||||
C60._ |
8077/2, Grade III 8148/2, Grade III |
Volume One: In Situ Coding |
Reportable = 2001+ |
|||
PIN III (prostatic intraepithelial neoplasia, Grade III or 3) |
||||||
C61.9 |
8148/2, Grade III |
Volume One: In Situ Coding |
Has never been reportable to the CCR |
|||
SIN III (squamous intraepithelial neoplasia, Grade III or 3) |
||||||
All sites (Excluding Cervix) |
8077/2, Grade III |
Volume One: In Situ Coding SEER Program Manual |
Reportable = 2014+ |
|||
VAIN III (vaginal intraepithelial neoplasia, Grade III or 3) VIN III (vulvar intraepithelial neoplasia, Grade III or 3) |
||||||
C52._ C51._ |
8077/2, Grade III |
Volume One: In Situ Coding DSQC Memo #2002-01 PAQC Memo #2012-03 |
Reportable = 1992+ |
LYMPHATIC & HEMATOPOIETIC DISEASES---SUBSEQUENT DIAGNOSES The reportable terms noted above are used ONLY for solid tumors. For reportability rules of hematopoietic and lymphoid neoplasms, refer to the Hematopoietic and Lymphoid Neoplasm Database and Coding Manual. |
||
DATE DIAGNOSIS YEAR |
||
1st Primary |
2nd primary |
Reference |
Prior to 2001 |
Prior to 2001 |
SEER Hematopoietic Manual & Database |
2001--2009 |
2001--2009 |
ICD-O-3 table in Volume I, Appendix R SEER Hematopoietic Manual & Database |
Prior to 2001 |
2001-2009 |
ICD-O-3 table in Volume I, Appendix R SEER Hematopoietic Manual & Database |
2010 |
2010 |
SEER Hematopoietic Manual & Database |
Prior to 2010 |
2010 |
SEER Hematopoietic Manual & Database |
Clarification on Reportability |
|||
Carcinoid tumors, NOS of the Appendix (C18.1) |
8240/3 effective with 2015
8240/1 is obsolete in 2015 |
ICD-O-3 Updates 2015 SEER Program Manual- Reportability |
Reportable = 2015 + |
Dysplasia (severe, high grade) |
Only reportable when it is specified as carcinoma in situ or pathologist documents as being synonymous with carcinoma in situ. |
||
GIST – Gastrointestinal stromal tumors |
Only reportable if identified as being in situ; is identified as malignant on the pathology report; or the patient is undergoing treatment as if it is malignant. SEER SINQ #20140088 |
||
Liver |
Report liver cases with an LR-5 or LR-5V based on the 2014 American College of Radiology Definitions, http://nrdr.acr.org/lirads
Do not report liver cases based only on an LI-RADS category of LR-4. |
||
Lymphoma In situ |
SEER Hematopoietic Manual & Database SEER SINQ #20130042 |
Has always been non-reportable |
|
PUNLMP – Papillary Urothelial Neoplasm of low malignant potential |
Not reportable. Pre malignant growths in the upper urinary tract (renal pelvis, ureters, urinary bladder part of urethra). |
||
Pancreas (C25.0-C25.9) |
Neuroendocrine tumor when dx is insulinoma (8240/3 or 8151/3)
Cystic pancreatic endocrine neoplasm (CPEN) (8150/3)
Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 1 (8240/3)
Cystic pancreatic endocrine neoplasm specified as neuroendocrine tumor, Grade 2 (8249/3)
Solid pseudopapillary neoplasm of pancreas (8452/3)
Non-invasive mucinous cystic neoplasm (MCN) of pancreas with high grade dysplasia (8470/2)
NOTE: Term high-grade dysplasia replaces term mucinous cystadenocarcinoma, non-invasive |
Reportable = 2015 + | |
Pituitary Gland (C75.1)
|
Rathke pouch tumor (9350/1)
NOTE: Rathke cleft cyst and Rathke pouch tumor are different conditions. Rathke cleft cyst is not reportable. |
Reportable = 2001 + |
|
Testes (C62.0-C62.9) |
Mature teratoma of testes in adult
Adult defined as post puberty
NOTE: Do not report if it is unknown whether patient is pre or post pubescence. |
Reportable = 2015 + |
|
Urine cytology - Positive for malignancy |
SEER Program Manual- Reportability SEER INQ #20120079 Volume One: Ambiguous Diagnostic Reportable Terms |
Reportable = 2013 + |
|
Venous angioma /Venous hemangioma |
Venous angiomas are NOT reportable wherever they arise. The primary site for venous hemangioma arising in the brain is blood vessel (C490). The combination of 9122/0 (Venous hemangioma) and C490 is not reportable.
NOTE: This is a venous abnormality, previously referred to as venous angiomas and currently referred to as developmental venous anomalies (DVA) |